Exhibit 99.2

img193038000_0.jpg

 

Arcadia Biosciences, Inc.

Consolidated Balance Sheets

(Unaudited)

(In thousands, except share data)

 

 

 

 

 

 

 

 

 

 

June 30, 2026

 

 

December 31, 2025

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

4,178

 

 

$

259

 

Short-term investments

 

 

 

 

 

4,304

 

Accounts receivable and other receivables, net of allowance for credit loss
   of $559 as of June 30, 2026 and December 31, 2025

 

 

559

 

 

 

425

 

Inventories

 

 

930

 

 

 

1,212

 

Prepaid expenses and other current assets

 

 

72

 

 

 

156

 

Total current assets

 

 

5,739

 

 

 

6,356

 

Property and equipment, net

 

 

 

 

 

8

 

Intangible assets, net

 

 

39

 

 

 

39

 

Other noncurrent assets

 

 

115

 

 

 

143

 

Total assets

 

$

5,893

 

 

$

6,546

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$

1,383

 

 

$

1,789

 

Other current liabilities

 

 

263

 

 

 

270

 

Total current liabilities

 

 

1,646

 

 

 

2,059

 

Common stock warrant and option liabilities

 

 

3,614

 

 

 

347

 

Total liabilities

 

 

5,260

 

 

 

2,406

 

Commitments and contingencies (Note 13)

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Common stock, $0.001 par value—150,000,000 shares authorized as
   of June 30, 2026 and December 31, 2025; 2,181,715 and 1,373,120 shares issued
   and outstanding as of June 30, 2026 and December 31, 2025, respectively

 

 

66

 

 

 

65

 

Additional paid-in capital

 

 

292,435

 

 

 

285,292

 

Accumulated deficit

 

 

(291,868

)

 

 

(281,217

)

Total stockholders' equity

 

 

633

 

 

 

4,140

 

Total liabilities and stockholders’ equity

 

$

5,893

 

 

$

6,546

 

 

 

1


 

Arcadia Biosciences, Inc.

Consolidated Statements of Operations and Comprehensive Income (Loss)

(Unaudited)

(In thousands, except share data and per share data)

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

 

2026

 

 

 

2025

 

 

 

2026

 

 

 

2025

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Product

 

$

1,443

 

 

$

1,455

 

 

$

2,543

 

 

$

2,655

 

Total revenues

 

 

1,443

 

 

 

1,455

 

 

 

2,543

 

 

 

2,655

 

Operating expenses (income):

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues

 

 

812

 

 

 

824

 

 

 

1,512

 

 

 

1,506

 

Research and development

 

 

 

 

 

9

 

 

 

 

 

 

9

 

Gain on sale of intangible assets

 

 

 

 

 

 

 

 

 

 

 

(750

)

Change in fair value of contingent consideration

 

 

 

 

 

(1,000

)

 

 

 

 

 

(2,000

)

Selling, general and administrative

 

 

1,127

 

 

 

2,123

 

 

 

2,306

 

 

 

3,861

 

Total operating expenses

 

 

1,939

 

 

 

1,956

 

 

 

3,818

 

 

 

2,626

 

(Loss) Income from continuing operations

 

 

(496

)

 

 

(501

)

 

 

(1,275

)

 

 

29

 

Interest income

 

 

2

 

 

 

9

 

 

 

7

 

 

 

216

 

Credit loss

 

 

 

 

 

(4,489

)

 

 

 

 

 

(4,489

)

Other (loss) income, net

 

 

(2,781

)

 

 

1,071

 

 

 

(4,285

)

 

 

1,071

 

Loss on January 2026 Inducement Offer

 

 

 

 

 

 

 

 

(2,877

)

 

 

 

Valuation loss on June 2026 PIPE

 

 

(5,423

)

 

 

 

 

 

(5,423

)

 

 

 

Change in fair value of common stock warrant and option liabilities

 

 

3,083

 

 

 

(548

)

 

 

4,274

 

 

 

1,314

 

Issuance and offering costs

 

 

(651

)

 

 

 

 

 

(1,072

)

 

 

 

Net loss attributable to common stockholders

 

$

(6,266

)

 

$

(4,458

)

 

$

(10,651

)

 

$

(1,859

)

Net loss per share attributable to common stockholders:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

(2.09

)

 

$

(3.26

)

 

$

(4.19

)

 

$

(1.36

)

Diluted

 

$

(2.09

)

 

$

(3.26

)

 

$

(4.19

)

 

$

(1.36

)

Weighted-average number of shares used in per share
   calculations:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

2,992,555

 

 

 

1,367,040

 

 

 

2,540,234

 

 

 

1,366,553

 

Diluted

 

 

2,992,555

 

 

 

1,367,040

 

 

 

2,540,234

 

 

 

1,366,553

 

 

2


 

Arcadia Biosciences, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

 

 

Six Months Ended June 30,

 

 

 

 

2026

 

 

 

2025

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

Net loss

 

$

(10,651

)

 

$

(1,859

)

Adjustments to reconcile net loss to cash used in operating activities:

 

 

 

 

 

 

Change in fair value of common stock warrant and option liabilities

 

 

(4,274

)

 

 

(1,314

)

Change in fair value of contingent consideration

 

 

 

 

 

(2,000

)

Issuance and offering costs

 

 

1,072

 

 

 

 

Valuation loss on June 2026 PIPE

 

 

5,423

 

 

 

 

Loss on January 2026 Inducement Offer

 

 

2,877

 

 

 

 

Depreciation

 

 

8

 

 

 

28

 

Lease amortization

 

 

 

 

 

117

 

Amortization of note receivable

 

 

 

 

 

(69

)

Gain on sale of intangible assets

 

 

 

 

 

(750

)

Gain on receipt of Above Food Ingredients, Inc. common stock

 

 

 

 

 

(1,067

)

Unrealized loss subsequent to receipt of Above Food Ingredients, Inc. common stock

 

 

4,304

 

 

 

 

Stock-based compensation

 

 

29

 

 

 

164

 

Credit loss

 

 

 

 

 

4,489

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable and other receivables

 

 

(134

)

 

 

(417

)

Inventories

 

 

282

 

 

 

(585

)

Prepaid expenses and other current assets

 

 

84

 

 

 

544

 

Other noncurrent assets

 

 

 

 

 

(56

)

Accounts payable and accrued expenses

 

 

(431

)

 

 

(630

)

Amounts due to related parties

 

 

 

 

 

(30

)

Other current liabilities

 

 

(7

)

 

 

(57

)

Operating lease liabilities

 

 

 

 

 

(129

)

Net cash used in operating activities

 

 

(1,418

)

 

 

(3,621

)

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

Proceeds from sale of intangible assets

 

 

 

 

 

750

 

Net cash provided by investing activities

 

 

 

 

 

750

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

Proceeds from June 2026 PIPE

 

 

4,000

 

 

 

 

Payments of offering costs relating to June 2026 PIPE

 

 

(395

)

 

 

 

Proceeds from January 2026 Inducement Offer

 

 

2,082

 

 

 

 

Payments of offering costs relating to January 2026 Inducement Offer

 

 

(350

)

 

 

 

Proceeds from ESPP purchases

 

 

 

 

 

5

 

Net cash provided by financing activities

 

 

5,337

 

 

 

5

 

Net increase (decrease) in cash and cash equivalents

 

 

3,919

 

 

 

(2,866

)

Cash and cash equivalents — beginning of period

 

 

259

 

 

 

4,242

 

Cash and cash equivalents — end of period

 

$

4,178

 

 

$

1,376

 

NONCASH INVESTING AND FINANCING ACTIVITIES:

 

 

 

 

 

 

Accrued legal fees included in offering costs related to June 2026 PIPE

 

$

55

 

 

$

 

Preferred investment options issued to placement agent and included in offering costs related to June 2026 PIPE

 

$

201

 

 

$

 

Preferred investment options issued to placement agent and included in offering costs related to January 2026 Inducement Offer

 

$

71

 

 

$

 

Warrant and option modifications included in Loss on January 2026 Inducement Offer

 

$

555

 

 

$

 

 

# # #

3